The epithelial cell-adhesion molecule (EpCAM)-based CellSearch® was the first FDA-approved platform for CTC analysis, providing prognostic information in metastatic breast, prostate, and colorectal cancer [9]. The gene discussed is EPCAM; the disease is colorectal cancer.